Popular Trials
Monoclonal Antibodies
Nipocalimab for Lupus Nephritis
This trial is testing nipocalimab, a medicine that reduces harmful antibodies, in patients with active Lupus Nephritis, a severe kidney condition caused by lupus. The study will last over a year and will monitor safety and effectiveness.
Monoclonal Antibodies
Ravulizumab for Lupus Nephritis and IgA Nephropathy
This trial is testing the safety and effectiveness of a drug called ravulizumab, given through a vein, in patients with specific kidney diseases. The drug aims to reduce kidney damage by blocking part of the immune system.
CAR T-cell Therapy
CAR T-Cell Therapy for Lupus Nephritis
This trial is testing a new treatment that uses modified immune cells to target and destroy harmful cells in adults with severe kidney inflammation from lupus that doesn't respond to usual treatments.
Anti-metabolites
Mycophenolate Mofetil for Pediatric Lupus Nephritis
This trial is a 1-year study with two parts. It is double-blinded, meaning neither the participants nor the researchers know which treatment they are receiving. The trial is comparing two different treatment approaches
Popular Filters
Trials for LN Patients
Iptacopan for Lupus Nephritis
This trial is testing a new medication called iptacopan to see if it can help patients when added to their usual treatments. It targets patients who are already receiving standard care and aims to make their current treatments work better.
Monoclonal Antibodies
VIB4920 for Lupus Nephritis
This trial is testing a new drug called VIB4920, along with two other medications, MMF and prednisone, to treat kidney problems caused by lupus. The study involves people who have active lupus nephritis, a serious kidney condition. The treatment aims to reduce inflammation and calm the immune system to help improve kidney function. MMF has been established as an effective treatment for lupus nephritis, often used in combination with other medications like prednisone.
Monoclonal Antibodies
Anifrolumab for Lupus Nephritis
This trial is testing an IV medication called anifrolumab in adults with severe lupus nephritis. The goal is to see if it can reduce inflammation and prevent kidney damage. All patients will also receive standard treatments. Anifrolumab is approved by the FDA for treating moderate to severe systemic lupus erythematosus (SLE).
Monoclonal Antibodies
Ianalumab + Standard Therapy for Lupus Nephritis
This trial will test how well ianalumab injections work and how safe they are for adults with a type of kidney inflammation caused by lupus. The medication is given under the skin at regular intervals. It aims to reduce kidney inflammation by calming the immune system.
Trials for Lupus Patients
Monoclonal Antibodies
CABA-201 for Lupus
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
Trials for Anti-dsDNA Positive Patients
Monoclonal Antibodies
CABA-201 for Lupus
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
Immunomodulator
Povetacicept for Autoimmune Kidney Diseases
This trial will assess if a drug (povetacicept) is safe & potentially beneficial in treating IgA nephropathy, membranous nephropathy & lupus nephritis. Participants receive drug every 4 weeks for 6 months, with the possibility of a 6-month extension.
CAR T-cell Therapy
Rapcabtagene Autoleucel for Lupus Nephritis
"This trial aims to compare the effectiveness and safety of rapcabtagene autoleucel with the standard treatment in patients with lupus and kidney inflammation that has not responded to standard treatment."
CAR T-cell Therapy
NKX019 + Cyclophosphamide for Lupus Nephritis
This trial will test a new treatment called NKX019 in participants with lupus kidney disease. The study will focus on assessing the safety and how well the treatment is tolerated by the participants.
Trials With No Placebo
Monoclonal Antibodies
Daratumumab for Lupus Nephritis
This trial is testing daratumumab, a medication that helps the immune system, in patients with active lupus nephritis. The goal is to see if it can help these patients by reducing kidney damage caused by their disease.
Anti-metabolites
ADI-001 for Lupus Nephritis
This trial is testing a new treatment for lupus nephritis in multiple centers. It will involve different stages like screening, treatment, and follow-up to find the appropriate dose and assess its safety and effectiveness
Monoclonal Antibodies
CABA-201 for Lupus
This trial tests a new cell therapy called CABA-201 for patients with active lupus. It aims to help those whose disease is not well-controlled by current treatments. Patients first get standard medications to prepare their bodies, then receive CABA-201 to help manage their immune system.
View More Related Trials
Frequently Asked Questions
Introduction to lupus nephritis
What are the top hospitals conducting lupus nephritis research?
In the realm of lupus nephritis, several hospitals are driving forward with clinical trials that hold promise for patients suffering from this challenging condition. Among them is the Prolato Clinical Research Center (PCRC) in Houston, which currently has two active trials dedicated to lupus nephritis. Although PCRC's involvement may seem relatively recent, having recorded its first trial in 2019, their commitment to advancing knowledge and treatment options for this disease is commendable. Similarly, Reliant Medical Research in Miami is making strides with two ongoing lupus nephritis trials and holds a unique distinction as they have already secured consent to conduct a groundbreaking study starting 2023.
Not far behind is Novartis Investigative Site located in sunny San Diego where two active lupus nephritis trials are underway. Their initiation of research into lupus nephritis began more recently than others when they recorded their first trial in 2020; nevertheless, their contribution shows immense potential for advancements on the horizon. Meanwhile, at the University of Colorado in Denver, researchers are working diligently on one active clinical trial addressing lupus nephritis after recording their initial effort back in 2011.
Last but not least among these leading institutions is Northwell Health situated in Great Neck. While they have one ongoing trial focused on understanding and treating this complex condition today, it's worth noting that Northwell Health has a rich history of conducting four previous studies related to lupus nephritis since embarking on their journey towards advancement back in 2016.
These hospitals represent beacons of hope for those who battle against lupus nephritis daily. The dedication showcased by these esteemed institutions indicates a promising future where new treatments and breakthroughs bring us closer to improving the lives of individuals affected by this debilitating disease
Which are the best cities for lupus nephritis clinical trials?
When it comes to lupus nephritis clinical trials, several cities emerge as prominent hubs for research and development. Houston, Texas; New york, New York; Miami, Florida; Atlanta, Georgia; and El Paso, Texas all host a significant number of active trials exploring innovative treatment options. These trials investigate the effectiveness of various drugs such as zetomipzomib, Daxdilimab Arm 1, Nipocalimab, VIB4920, Anifrolumab among others in managing lupus nephritis. Individuals seeking cutting-edge therapies and opportunities to contribute to medical advancements can look to these cities as potential centers for participation in clinical trials aimed at improving outcomes for lupus nephritis patients.
Which are the top treatments for lupus nephritis being explored in clinical trials?
The exciting world of clinical trials is paving the way for advancements in lupus nephritis treatment. Among the top contenders are obinutuzumab and anifrolumab, both currently being explored in active trials. Obinutuzumab has shown promise with two ongoing trials and a total of three all-time lupus nephritis trials since its introduction in 2015. Similarly, anifrolumab is making its mark with one active trial and two all-time lupus nephritis trials, also first listed in 2015. These innovative treatments offer hope for improved outcomes and brighter futures for individuals battling this complex condition.
What are the most recent clinical trials for lupus nephritis?
Exciting advancements in the treatment of lupus nephritis have emerged through recent clinical trials. One notable trial investigated the efficacy and safety of voclosporin, a promising candidate for managing this condition. Another study explored zetomipzomib, combined with standard-of-care treatments, as a potential therapeutic approach. Additionally, an innovative phase 1 trial examined KYV-101 CAR-T cells with lymphodepletion conditioning to target lupus nephritis specifically. Lastly, Daxdilimab Arm 1 showcased its potential benefits in mitigating symptoms associated with this chronic autoimmune disease. With these groundbreaking trials unveiling new possibilities for individuals affected by lupus nephritis, there is renewed hope on the horizon.
What lupus nephritis clinical trials were recently completed?
In the realm of lupus nephritis clinical trials, there have been several recent completions that hold great promise for advancing treatment options. Notably, Janssen Research & Development, LLC concluded a trial in September 2020 focused on assessing the efficacy of standard-of-care treatments. Furthermore, in September 2018, Novartis Pharmaceuticals wrapped up their CFZ533 trial aimed at exploring potential therapeutic interventions. Another significant milestone was achieved by Kezar Life Sciences with the completion of their KZR-616 study in March 2018. These collective efforts signify a dedicated pursuit to improve outcomes for individuals with lupus nephritis and ignite optimism within the medical community and patient population alike